Relapsing De Novo Membranous Nephropathy.

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Membranous glomerulopathy (MG) in kidney allografts can be primary (immune-mediated) or de novo.
• While treatments for primary MG are advancing (e.g., anti-PLA2R, THS7A therapies), effective strategies for de novo MG remain unclear.
• Relapsing de novo MG post-transplant is exceptionally rare, with limited reported cases.

Observation:

• This report details a kidney transplant recipient who developed recurrent de novo membranous glomerulopathy.
• The patient exhibited no signs of kidney allograft rejection during the disease recurrence.
• The patient demonstrated a positive clinical response to rituximab therapy.

Findings:

• Rituximab treatment led to a favorable outcome in a rare case of relapsing de novo membranous glomerulopathy.
• The successful use of rituximab suggests its potential efficacy in managing de novo MG, even without concurrent rejection.
• This case highlights the distinct immune pathophysiology and clinical course of de novo MG compared to primary forms.

Implications:

• This case provides valuable insights into the management of de novo membranous glomerulopathy in kidney transplant recipients.
• Rituximab emerges as a potential therapeutic option for relapsing de novo MG, warranting further investigation.
• Understanding the specific pathophysiology of de novo MG is crucial for developing targeted treatment strategies.